Givosiran is a prescription medicine used in adults to treat acute intermittent porphyria (AIP). It is an RNA interference therapeutic which targets the production of the enzyme aminolevulinic acid synthase 1 (ALAS1). Givosiran works by reducing the amount of ALAS1 in the body, which helps to reduce episodes of abdominal pain, nausea, vomiting, and other symptoms associated with AIP. Givosiran is administered as a once-monthly subcutaneous injection.
Givosiran is a medication specifically designed to treat acute hepatic porphyria (AHP) in adults [1, 2]. AHP is a rare genetic disorder that affects the liver and can cause life-threatening attacks on the nervous system [1].
Here's a closer look at Givosiran:
- Mechanism of action: AHP is caused by a genetic mutation that disrupts the production of heme, an essential molecule in red blood cells. Givosiran is a small interfering RNA (siRNA) medication [2]. siRNAs target specific genes and prevent them from producing proteins. In the case of Givosiran, it targets a gene called ALAS1, which is overactive in AHP and leads to a buildup of toxic substances. By reducing ALAS1 activity, Givosiran helps regulate heme production and prevent the accumulation of toxins that cause AHP attacks [2].
- Administration: Givosiran is given as a monthly injection under the skin by a healthcare professional [2, 4].
Benefits of Givosiran:
- AHP attack prevention: Previously, there weren't any medications specifically approved to prevent AHP attacks. Givosiran is a significant advancement as it helps prevent these attacks by regulating the underlying cause [2].
- Targeted therapy: Givosiran acts at the gene level, targeting the specific cause of AHP, offering a more precise approach to treatment compared to traditional therapies that may have broader effects [2].
Important Considerations:
- New medication: Givosiran is a relatively new medication, and long-term effects are still being studied [2].
- Not a cure: Givosiran is a treatment for AHP, not a cure. It helps manage the condition and prevent attacks, but it doesn't completely eliminate the genetic mutation [2].
- Potential side effects: Like any medication, Givosiran can cause side effects, although these are generally mild and manageable. Some potential side effects include injection site reactions, fatigue, headache, and infusion reactions [4].
Overall
Givosiran is a promising new treatment for acute hepatic porphyria. It offers a targeted approach to prevent AHP attacks and improve the lives of patients with this rare genetic condition. If you have AHP or suspect you might, it's important to consult with your doctor to discuss if Givosiran is a suitable treatment option for you.